High Court decision: Technical know-how fee is capital expenditure; royalty payment is revenue expenditure.

The High Court ruled in favor of the Revenue regarding the technical know-how fee, determining a portion as capital expenditure due to enduring benefits provided by the acquired knowledge. However, the court sided with the assessee on the royalty payment issue, considering it as revenue expenditure linked to sales. The appeal was disposed of without costs, and any pending petitions were closed.

---

---

Issues Involved:
1. Whether the payment of technical know-how fee was revenue expenditure or capital in nature.
2. Whether the expenditure on account of payment of royalty was revenue in nature.

Issue-wise Detailed Analysis:

Issue 1: Technical Know-how Fee as Revenue or Capital Expenditure
The assessee paid Rs. 2,75,85,300/- towards technical know-how fee and claimed it as revenue expenditure. The Assessing Officer (AO) allowed only 1/6th of the amount as a deduction under Section 35AB of the Income Tax Act, treating the rest as capital expenditure. The CIT (Appeals) modified this, treating 75% of the fee as revenue expenditure and 25% as capital. The Tribunal, however, allowed the entire expenditure as revenue, leading to the Revenue's appeal.

The Tribunal analyzed the agreement and applied the six tests from the Jonas Woodhead & Sons (India) Limited vs. CIT case, concluding that there was no new business started based on the technical know-how. The Tribunal noted that the technical know-how and Germplasm were acquired after the commencement of business, and the agreement provided for mutual exchange of improvements and developments. The Tribunal found that the technical know-how did not provide an enduring benefit due to rapid advancements in biotechnology, aligning with the Supreme Court's guidance in Alembic Chemicals Works Company vs. CIT.

However, the High Court disagreed, noting that the Germplasm and technical know-how provided enduring benefits, as they were crucial for the assessee's revenue generation. The agreement's terms, including the right to use, produce, and sell the Germplasm and technical know-how, indicated a long-term benefit. The court found the Tribunal's assumption that the Germplasm was returnable incorrect, as the agreement stipulated its return only upon termination.

The court concluded that the CIT (Appeals) correctly apportioned the expenditure, treating a part as capital expenditure. Thus, the question of whether the technical know-how fee was revenue or capital expenditure was answered in favor of the Revenue.

Issue 2: Royalty Payment as Revenue Expenditure
The assessee paid Rs. 47,34,306/- as royalty and claimed it as revenue expenditure. The AO treated 1/4th of the royalty payment as capital expenditure. The CIT (Appeals) and the Tribunal treated the entire royalty payment as revenue expenditure.

The High Court agreed with the Tribunal, noting that the royalty was linked to the percentage of consideration received from the sale of products produced using the Germplasm and technical know-how. This linkage to sales indicated that the royalty payment was a recurring expense directly related to the assessee's revenue generation.

Thus, the question of whether the royalty payment was revenue expenditure was answered in favor of the assessee.

Conclusion:
The High Court disposed of the appeal, answering the first question in favor of the Revenue and the second in favor of the assessee. No order as to costs was made, and any pending miscellaneous petitions were closed.

---